Indeed Foxp3+ T cells manage to successfully pervade, and often dominate the tumor-specific immune response; Foxp3+ to Foxp3− T cell ratios in the range 0.5–1:1 have been described in some tumors (12, 14, 15). This evidence concerns the gene FOXP3 and neoplasm.